Figure 2
From: Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer
Effect of bosutinib on viability of NSCLC cell lines is independent of KRAS status. The KRAS mutant (A) and wildtype (B) NSCLC or Normal Human Bronchial Epithelial (NHBE) cells were seeded onto 96-well plates for 24 h. The cells were treated with various concentrations (0–10 μM) of bosutinib for 72 h followed by cell viability assay measured by CellTitre Glo. The cell viability results were normalized to DMSO-treated controls and expressed in percentage. (C) Four NSCLC cells were treated with bosutinib for 72 h at different concentrations. Caspase3/7 activities were measured using Caspase-Glo 3/7 luminescent assay kit. The enzymatic activity is expressed as the value with respect to untreated cells.